OLEMA PHARMACEUTICALS INC. - COMMON STOCK

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 Aug 2024 16:30:00 By Nasdaq GlobeNewswire

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 Jul 2024 16:29:00 By Nasdaq GlobeNewswire

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 Jun 2024 16:28:00 By Nasdaq GlobeNewswire

Olema Oncology to Participate in Upcoming Investor Conferences in June

28 May 2024 07:03:00 By Nasdaq GlobeNewswire

Olema Oncology Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 ESMO Breast Cancer Congress

15 May 2024 07:01:00 By Nasdaq GlobeNewswire

Olema Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update

08 May 2024 16:02:00 By Nasdaq GlobeNewswire

Olema Oncology Announces New Clinical Data for Palazestrant in Combination with Ribociclib to be Presented at the 2024 ESMO Breast Cancer Annual Congress

08 May 2024 07:02:00 By Nasdaq GlobeNewswire

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 May 2024 16:37:00 By Nasdaq GlobeNewswire

Olema Oncology to Participate in Upcoming Investor Conferences in May

01 May 2024 07:02:00 By Nasdaq GlobeNewswire

Olema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual Conference

08 Apr 2024 16:30:00 By Nasdaq GlobeNewswire

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 Apr 2024 16:29:00 By Nasdaq GlobeNewswire

Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update

11 Mar 2024 16:03:00 By Nasdaq GlobeNewswire

Olema Oncology Announces Publication of Data Highlighting Palazestrant’s Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with CDK4/6 Inhibitors

06 Mar 2024 07:03:00 By Nasdaq GlobeNewswire

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 Mar 2024 16:30:00 By Nasdaq GlobeNewswire

Olema Oncology to Participate in Upcoming Investor Conferences

06 Feb 2024 07:01:00 By Nasdaq GlobeNewswire

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 Feb 2024 16:30:00 By Nasdaq GlobeNewswire

Olema Oncology Nominates OP-3136, an Orally Bioavailable KAT6 Inhibitor, as a Development Candidate

08 Jan 2024 08:12:48 By Nasdaq GlobeNewswire

Olema Oncology to Present at 42nd Annual J.P. Morgan Healthcare Conference

02 Jan 2024 16:01:00 By Nasdaq GlobeNewswire

Olema Oncology Announces Palazestrant Demonstrates Attractive Combinability with CDK4/6 Inhibitors Ribociclib and Palbociclib in Phase 1b/2 Studies

05 Dec 2023 12:27:48 By Nasdaq GlobeNewswire

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 Dec 2023 16:29:00 By Nasdaq GlobeNewswire